Upstream Bio, Inc.

UPB

CIK 0002022626 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$668K
↑+9.0% +$55Kvs FY2024 (Q4)
Gross Profit
$668K
↑+9.0% +$55Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
25/100
  • Profitability
    0ROIC -31.3% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 26.15 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.01x (1.0+ = capital-efficient)
  • Growth
    47Revenue YoY +9.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -5539.4% · trend -2343.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$118K
investment in PP&E
Stock-based comp (TTM)
$10M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$354M
everything owned
Total liabilities
$14M
everything owed
Stockholders' equity
$340M
shareholder claim

Recent performance · 12 quarters

Revenue↑+9.0% +$55K
$668K
Net Income↓-111.0% -$18M
$-34M
Free Cash Flow↑+70.8% +$131K
$-54K
Operating Margin↓-2426.9pts
-5539.4%

Drill down